OSE Immunotherapeutics SA
OSE Immunotherapeutics SA, headquartered in France, is a pioneering biotechnology company specialising in immunotherapy solutions for cancer and autoimmune diseases. Founded in 2012, OSE has rapidly established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapeutic products that harness the body’s immune system. The company’s core offerings include a diverse pipeline of monoclonal antibodies and vaccine candidates, distinguished by their unique mechanisms of action. Notable achievements include strategic partnerships and collaborations that enhance its market position, particularly in Europe and North America. OSE Immunotherapeutics is committed to advancing the frontiers of immunotherapy, aiming to provide effective treatments that address unmet medical needs in oncology and beyond.
DitchCarbon Score
How does OSE Immunotherapeutics SA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
OSE Immunotherapeutics SA's score of 29 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
OSE Immunotherapeutics SA's reported carbon emissions
OSE Immunotherapeutics SA, headquartered in France, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, OSE Immunotherapeutics SA does not appear to have established any formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. The lack of emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the broader context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. However, without specific commitments or data from OSE Immunotherapeutics SA, it is unclear how they plan to address climate change and carbon emissions in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
OSE Immunotherapeutics SA is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
